Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.

This series demonstrates the effective use of JAK inhibition with ruxolitinib to control pathological immune activation in critically ill patients with secondary HLH and otherwise limited therapeutic options. JAK inhibition is also an area of urgent investigation for the treatment of cytokine storm associated with COVID-19.